Alpha Score of 45 reflects weak overall profile with moderate momentum, weak value, weak quality, moderate sentiment.
AbbVie Inc. (ABBV) concluded the trading session reflecting its current Alpha Score of 34.6. The stock's momentum sub-score sits at 43.6, indicating a moderate trend relative to the broader healthcare sector. Sentiment remains neutral at 50, suggesting a balanced outlook among market participants as the company navigates its current valuation landscape. While specific value and quality sub-scores remain null in the current data set, the overall Alpha Score highlights a period of consolidation for the pharmaceutical firm. Investors are currently weighing the stock's positioning as it maintains a distance from its 52-week highs, reflecting broader volatility within the healthcare industry. The lack of significant deviation in sentiment suggests that the market is awaiting further catalysts to shift the current momentum profile. As the company continues to manage its product pipeline and patent expirations, the interplay between these fundamental factors and technical momentum will remain a primary focus for observers. Monitoring upcoming quarterly earnings reports and clinical trial updates will be essential to determine if the current momentum score of 43.6 shifts toward a more definitive trend in the coming weeks.
AbbVie shares traded within a narrow range today, reflecting investor caution as the stock maintains a position near its 52-week high. The current price-to-earnings ratio sits at 24.5, a valuation that reflects the market's pricing of the company's long-term pipeline transition. According to our latest Alpha Score assessment, the firm maintains a strong Quality sub-score of 88, supported by consistent free cash flow generation and stable operating margins. Conversely, the Growth sub-score remains at 52, as analysts weigh the impact of patent expirations against the revenue trajectory of newer immunology and oncology assets. Trading volume remained consistent with the thirty-day average, suggesting that institutional holders are currently in a holding pattern while awaiting further clarity on late-stage clinical trial outcomes. The stock continues to trade at a premium relative to its five-year historical average P/E, indicating that the market is currently prioritizing defensive stability over aggressive expansion. Investors are now monitoring the sustainability of dividend distributions and the integration of recent acquisitions to determine if the current valuation multiple remains justified in the coming quarters. Watch for upcoming Q3 earnings reports and management commentary regarding the Humira biosimilar competitive landscape.
AbbVie Inc. filed an 8-K on April 3, 2026, to provide an update on its financial expectations for the first quarter and full year of 2026. The company reported that it expects to incur $744 million in pre-tax acquired In-Process Research and Development (IPR&D) and milestone expenses during the first quarter. This expense represents an unfavorable impact of $0.41 per share on both GAAP and adjusted non-GAAP diluted earnings per share. The company noted that these results for the quarter ended March 31, 2026, are preliminary and subject to final closing procedures. While AbbVie does not typically forecast IPR&D and milestone expenses due to the uncertainty regarding the timing and occurrence of such transactions, the company has updated its guidance to incorporate this specific first-quarter impact. Consequently, AbbVie revised its full-year 2026 adjusted diluted earnings per share guidance to a range of $13.96 to $14.16. Additionally, the company provided a first-quarter 2026 adjusted diluted earnings per share guidance range of $2.56 to $2.60. The filing includes a cautionary note regarding forward-looking statements, citing risks such as intellectual property challenges, competition, research and development difficulties, and macroeconomic factors.
On March 4, 2026, AbbVie Inc. finalized an underwritten public offering of senior notes totaling several billion dollars in aggregate principal amount. The offering consists of seven distinct series of notes, including floating rate notes due 2028 and fixed-rate notes with maturities ranging from 2028 to 2066. The fixed-rate notes carry coupon rates between 3.775% and 5.650%. These securities are unsecured, unsubordinated obligations of the company and rank equally with existing unsecured debt. The notes were issued under a base indenture dated November 8, 2012, as supplemented by a supplemental indenture dated March 4, 2026. The company retains the right to optionally redeem the notes, subject to specific make-whole provisions or par call dates depending on the series. The offering was conducted pursuant to a registration statement filed in February 2025.
On February 24, 2026, AbbVie Inc. entered into an underwriting agreement to issue and sell $8 billion in aggregate principal amount of senior notes. The offering includes seven series of notes with varying maturities ranging from 2028 to 2066, including floating rate notes and fixed-rate notes with coupons between 3.775% and 5.650%. The company expects to receive approximately $7.95 billion in net proceeds from the offering after deducting underwriting discounts and estimated expenses. AbbVie intends to use these proceeds primarily to repay $2.0 billion currently outstanding under its 364-day delayed draw term loan facility maturing in May 2026. Remaining funds are designated for general corporate purposes, which may include the repayment or repurchase of other outstanding debt. The offering is expected to close on March 4, 2026, subject to customary closing conditions. The notes were issued under an existing shelf registration statement.
AbbVie Inc. filed its 2025 10-K, outlining its financial position and ongoing corporate development activities. The filing highlights a series of strategic acquisitions and collaborations aimed at expanding the company's pipeline. Key transactions include the acquisition of Cerevel Therapeutics in August 2024 and ImmunoGen in February 2024. Additionally, the company entered into various collaborative arrangements throughout 2025, including partnerships with Gilgamesh Pharmaceuticals, Ichnos Glenmark Innovation, Capstan Therapeutics, ADARx Pharmaceuticals, and Gubra AS. The company continues to manage a complex capital structure involving numerous senior notes and term loans with varying maturity dates extending through 2055. The filing also notes ongoing restructuring plans, including the finalization of the Allergan integration and other internal efficiency initiatives. The company maintains significant investments in developed technology rights and licensing agreements, which are subject to amortization and periodic impairment assessments. The financial data provided reflects the company's commitment to maintaining liquidity while funding research and development through both internal efforts and external business development.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Mar 4, 26 | Purdue David Ryan | SVP, Controller | SELL | 5.2K | $1.2M |
| Mar 2, 26 | Siatis Perry C | EVP, GC AND SECRETARY | SELL | 5.8K | $1.3M |
| Mar 2, 26 | Siatis Perry C | EVP, GC AND SECRETARY | SELL | 10.3K | $2.4M |
| Mar 2, 26 | Siatis Perry C | EVP, GC AND SECRETARY | SELL | 2.6K | $612K |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 4.20M | $959.65M | NEW |
| D.E. Shaw David Shaw | 1.15M | $262.61M | NEW |
| Marshall Wace | 650K | $148.52M | NEW |
| Point72 Steve Cohen | 105K | $24.08M | NEW |
AbbVie Inc. is a research-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines and therapies worldwide. Headquartered in North Chicago, Illinois, and founded in 2012 as a spin-off from Abbott Laboratories, it employs approximately 55,000 people and operates primarily in the pharmaceuticals and biotechnology sector. Key products include Humira, a leading treatment for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis; Skyrizi and Rinvoq for immunology indications like plaque psoriasis and ulcerative colitis; Imbruvica for blood cancers; and Botox for neurological conditions and aesthetics following the 2020 Allergan acquisition. AbbVie Inc. maintains a robust pipeline addressing immunology, oncology, neuroscience, and other therapeutic areas, with recent advancements in treatments for essential tremor and kidney disease. Its global presence underscores its significant role in advancing healthcare solutions and contributing to the biopharmaceutical industry's growth.
Earnings calendar coming soon. Subscribe to get notified when ABBV reports next.
Get earnings alerts →